Premium
Conventional radiotherapy versus concurrent chemoradiotherapy versus accelerated radiotherapy in locoregionally advanced carcinoma of head and neck: Results of a prospective randomized trial
Author(s) -
Ghosh–Laskar Sarbani,
Kalyani Nikhil,
Gupta Tejpal,
Budrukkar Ashwini,
Murthy Vedang,
Sengar Manju,
Chaukar Devendra,
Pai Prathamesh,
Chaturvedi Pankaj,
D'Cruz Anil,
Agarwal Jaiprakash
Publication year - 2016
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.23865
Subject(s) - medicine , mucositis , radiation therapy , chemoradiotherapy , clinical endpoint , head and neck squamous cell carcinoma , randomized controlled trial , dose fractionation , head and neck , head and neck cancer , carcinoma , basal cell , nuclear medicine , oncology , surgery
Background The purpose of this study was to report the results of a phase III, 3‐arm, randomized trial comparing conventional radiotherapy (RT) to concurrent chemoradiotherapy (CRT) and accelerated RT in advanced head and neck squamous cell carcinoma (HNSCC). Methods One hundred eighty‐six of 750 planned patients were randomized to receive one of the following treatment plans: RT (66–70 Gy/2 Gy fraction/5 fractions weekly; CRT of weekly cisplatin (30 mg/m 2 ) with the same RT dose; or accelerated RT alone of 66 to 70 Gy/2 Gy fraction/6 fractions weekly were available for analysis. The primary endpoint was locoregional control at 5 years. Results The mean follow‐up was 54 months. Among the 3 arms, CRT showed superior locoregional control (49%; p = .049). RT had lower grade ≥3 mucositis and late toxicity. Conclusion CRT is associated with significantly better locoregional control as compared to RT and accelerated RT with higher but acceptable acute and late toxicities. © 2015 Wiley Periodicals, Inc. Head Neck 38: 202–207, 2016